Evidence map›Paper›PMID 35192194›Full record

ArticleMedical physics2022

Adaptive carbon ion radiotherapy for locally advanced non-small cell lung cancer: Organ-sparing potential and target coverage.

Shubing Jia, Jian Chen, Ningyi Ma, Jingfang Zhao, Jingfang Mao, Guoliang Jiang, Jiade Lu, Kailiang Wu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shubing JiaDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Jian ChenDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Ningyi MaDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Jingfang ZhaoShanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Jingfang MaoDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Guoliang JiangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiade LuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Kailiang WuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNShanghai Genon Biological Products (China) · CNCenter for High Pressure Science & Technology Advanced Research · CN

Funding

Shanghai Municipal Health Commission Funds 201940334Shanghai Shen Kang Hospital Development Center Clinical Science and Technology Innovation Project SHDC12019X25
6 · The paper itself

Abstract

backgroundThe dose distribution of carbon ion radiotherapy (CIRT) for locally advanced non-small cell lung cancer (LANSCLC) is highly sensitive to anatomical changes. PURPOSE: To demonstrate the dosimetric benefits of adaptive CIRT for LANSCLC and compare the differences between patients with and without adaptive plans based on dosimetry and clinical effect factors. MATERIALS AND

methodsOf the 98 patients with LANSCLC receiving CIRT, 31 patients underwent replanning following re-evaluations that revealed changes that would have compromised the dose coverage of the target volume or violated dose constraints. Dosimetric parameters and clinical factors were compared between patients with and without adaptive plans. Multivariate analysis identified factors influencing the adaptive planning.

resultsThe median number of fractions delivered using adaptive plans was eight (range: 2-18). Adaptive plans ensured target coverage, and the maximum spinal cord dose was significantly decreased (p = 0.02). The median reduction in the maximum spinal cord dose was 10.4 Gy (relative biological effectiveness). Patients with adaptive plans had larger tumor volumes (p < 0.001); the median initial internal gross tumor volumes (iGTVs) of patients with adaptive and nonadaptive plans were 125.9 and 49.79 cm

conclusionsAn adaptive plan can effectively ensure target area coverage and protect normal tissues, especially in patients with large tumor volumes and substantial changes. iGTV volume changes and iGTV center movements are the main factors influencing adaptive planning. Weekly simulation computed tomography scans are necessary for treatment evaluation in patients with LANSCLC treated with CIRT.

Indexed as

Carcinoma, Non-Small-Cell LungHeavy Ion RadiotherapyLung NeoplasmsRadiotherapy, Intensity-ModulatedHumansOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-Assistedadaptive therapycarbon ion therapylocally advanced non-small cell lung cancer

Identifiers

PMID35192194
PMCPMC9314958
OpenAlexW4212897064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.